Should Ionis Pharmaceuticals' (IONS) Raised Revenue Guidance and Strong Q2 Results Prompt Investor Action?

• Ionis Pharmaceuticals recently reported that its second quarter 2025 revenue doubled year-over-year to US$452 million and raised its full-year 2025 revenue guidance to between US$825 million and US$850 million, reflecting strong performance driven by product launches and pipeline developments.
• Insider share sales and ongoing investments in lobbying efforts highlight both leadership activity and Ionis's attention to shaping the legislative landscape for biotech innovation.
• We'll take a look at how Ionis's raised revenue guidance and robust quarterly results strengthen the company's long-term investment narrative.

Find companies with promising cash flow potential yet trading below their fair value.

Ionis Pharmaceuticals Investment Narrative Recap

Ionis Pharmaceuticals' investment case rests on confidence in the expansion of its RNA-targeted therapies and the successful commercialization of late-stage assets. The company’s raise in 2025 revenue guidance and doubling of second quarter revenue add momentum, but do not materially resolve regulatory and execution risks surrounding upcoming FDA decisions for Donidalorsen and Olezarsen in larger indications, still the most important short-term catalyst and a key point of uncertainty.

Given these catalysts, the recent FDA approval of DAWNZERA (donidalorsen) for hereditary angioedema stands out. This milestone underscores Ionis’s ability to advance first-in-class therapies from development to approval, which is central to future growth prospects as the company readies additional launches and awaits regulatory decisions in sizeable patient populations.

Yet, while the headlines appear favourable, investors should also keep an eye on concerns around pricing pressure if Olezarsen moves into broader indications, because...

Read the full narrative on Ionis Pharmaceuticals (it's free!)

Ionis Pharmaceuticals is projected to reach $1.5 billion in revenue and $241.3 million in earnings by 2028. This outlook assumes a 16.7% annual growth in revenue and a $509.5 million increase in earnings from the current figure of -$268.2 million.

Uncover how Ionis Pharmaceuticals' forecasts yield a $73.03 fair value, in line with its current price.

Exploring Other Perspectives

Fair value estimates from the Simply Wall St Community span from US$36.19 to US$156.59 based on four analyses, reflecting a wide range of expectations. While revenue is forecast to climb 21.6 percent annually, the major risk remains the pressure on margins as Ionis expands into larger disease populations.

Explore 4 other fair value estimates on Ionis Pharmaceuticals - why the stock might be worth over 2x more than the current price!

Build Your Own Ionis Pharmaceuticals Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Ionis Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Ionis Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ionis Pharmaceuticals' overall financial health at a glance.

Seeking Other Investments?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• We've found 18 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 24 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• The end of cancer? These 28 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com